

		APPLICATION NO.: 10/613,749	ATTY. DOCKET NO.: C1037.70041US00
FORM PTO-1479A and B, modified PTO/SB/08)		FILING DATE: July 3, 2003	CONFIRMATION NO.: 6452
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: Arthur M. Krieg	
Sheet	1	of	3
		GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		BRAZOLOT MILLAN et al., CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15553-8.	
		CHU et al., CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing. J Immunol. 1999 Aug 1;163(3):1188-94.	
		COOPER et al., CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol. 2004 Nov;24(6):693-701.	
		HUNTER et al., Biodegradable microspheres containing group B Streptococcus vaccine: immune response in mice. Am J Obstet Gynecol. 2001 Nov;185(5):1174-9.	
		JONES et al., Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine. 1999 Aug 6;17(23-24):3065-71.	
		KOVARIK et al., Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens. Immunology. 2001 Jan;102(1):67-76.	
		KRIEG, Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007 May;117(5):1184-94.	
		KRIEG, Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008 Jan 7;27(2):161-7. Review.	
		KRUG et al., Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001 Jul;31(7):2154-63.	
		KRUG et al., Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001 Oct;31(10):3026-37.	

EXAMINER: /N. M. Minnifield/ (04/09/2009)	DATE CONSIDERED:
--	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/613,749		ATTY. DOCKET NO.: C1037.70041US00	
				FILING DATE: July 3, 2003		CONFIRMATION NO.: 6452	
				APPLICANT: Arthur M. Krieg			
				GROUP ART UNIT: 1645		EXAMINER: Nita M. Minnifield	
Sheet	2	of	3				

	LI et al., Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. <i>J Immunol.</i> 2007 Aug 15;179(4):2493-500.	
	MATSON et al., Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides. <i>Antisense Res Dev.</i> 1992 Winter;2(4):325-30.	
	McCLUSKIE et al., Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. <i>Curr Top Microbiol Immunol.</i> 2006;311:155-78.	
	MOLDOVEANU et al., CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. <i>Vaccine.</i> 1998 Jul;16(11-12):1216-24.	
	MOSEMAN et al., Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. <i>J Immunol.</i> 2004 Oct 1;173(7):4433-42.	
	REES et al., CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. <i>Antiviral Res.</i> 2005 Feb;65(2):87-95.	
	SANDLER et al., CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. <i>Cancer Res.</i> 2003 Jan 15;63(2):394-9.	
	STUNZ et al., Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. <i>Eur J Immunol.</i> 2002 May;32(5):1212-22.	
	TUETKEN et al., Ch. 6: Immune effects of bacterial DNA and their possible role in the pathogenesis of lupus. In: <i>Lupus: Molecular and Cellular Pathogenesis</i> , Kammar and Tsokos, Eds. Humana Press;1999:79-100.	
	VICARI et al., Development of targeted toll-like receptor agonists for cancer therapy. <i>PPO Focus.</i> 2007; 1(2):1-15.	
	VOLLMER et al., Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. <i>Antimicrob Agents Chemother.</i> 2004 Jun;48(6):2314-7.	
	VOLLMER et al., Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. <i>Immunology.</i> 2004 Oct;113(2):212-23.	
	VOLLMER, CpG motifs to modulate innate and adaptive immune responses. <i>Int Rev Immunol.</i> 2006 May-Aug;25(3-4):125-34. Abstract.	
	WALKER et al., Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. <i>Proc Natl Acad Sci U S A.</i> 1999 Jun 8;96(12):6970-5.	
	WANG et al., Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation. <i>Int Immunol.</i> 2003 Feb;15(2):223-31.	
	WARREN et al., APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. <i>J Immunol.</i> 2000 Dec 1;165(11):6244-51.	
	WEERATNA et al., Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. <i>Antisense Nucleic Acid Drug Dev.</i> 1998 Aug;8(4):351-6.	
	WEIGEL et al., Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. <i>Blood.</i> 2002 Dec 1;100(12):4169-76.	
	WEIGEL et al., CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. <i>Clin Cancer Res.</i> 2003 Aug 1;9(8):3105-14.	
	WOOLDRIDGE et al., Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance	

EXAMINER: /N. M. Minnifield/ (04/09/2009)	DATE CONSIDERED:
--	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/613,749	ATTY. DOCKET NO.: C1037.70041US00	
				FILING DATE: July 3, 2003	CONFIRMATION NO.: 6452	
				APPLICANT: Arthur M. Krieg		
				GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield	
Sheet	3	of	3			

		the efficacy of monoclonal antibody therapy of lymphoma. Blood. 1997 Apr 15;89(8):2994-8.	
		YI et al., CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J Immunol. 1996 Dec 1;157(11):4918-25.	

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER: /N. M. Minnifield/ (04/09/2009)	DATE CONSIDERED:
--	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.